Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent Duvelisib in Relapsed/Refractory CLL/SLL
NCT03961672Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- May 2020
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of duvelisib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by City of Hope. Started May 2020; status: active, not recruiting.
02
Drugs
duvelisib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03961672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03961672.